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Introduction: Within this large-scale study, we compared clinical symptoms, labora-
tory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to
find unique features.
Method: We searched all relevant literature published up to February 28, 2020.
Depending on the heterogeneity test, we used either random or fixed-effect models
to analyze the appropriateness of the pooled results. Study has been registered in
the PROSPERO database (ID 176106).
Result: Overall 114 articles included in this study; 52 251 COVID-19 confirmed
patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies)
were included. The most common symptom was fever; COVID-19 (85.6%, P < .001),
SARS (96%, P < .001), and MERS (74%, P < .001), respectively. Analysis showed that
84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had
an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P < .001) was lower
than SARS (13%, P < .001) and MERS (35%, P < .001) between all confirmed patients.
Conclusions: At the time of submission, the mortality rate in COVID-19 confirmed
cases is lower than in SARS- and MERS-infected patients. Clinical outcomes and find-
ings would be biased by reporting only confirmed cases, and this should be consid-
ered when interpreting the data.
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1 | INTRODUCTION
During the last two decades, coronaviruses have been recognized as
one of the most critical human pathogenic viruses that affect global
health and cause concern in the world health system.1 Coronavirus is
classified into four genera: alpha, beta, delta, and gamma. Major
human pathogenic viruses belong to the beta genus, including Severe
Acute Respiratory Syndrome (SARS), Middle East Respiratory Syn-
drome (MERS), and the 2019 novel coronavirus (COVID-19).2
Although coronaviruses are recognized as causes of the common
cold, SARS was the first coronavirus to cause a life-threatening respi-
ratory infection in humans. It was endemic in Guangzhou China in
2002-2003 and quickly spread to other countries in Asia, the Ame-
ricas, Europe, and South Africa. A total of 8098 SARS infected cases
and 774 deaths (about 10% mortality) were reported.3
About a decade later, MERS caused respiratory infection in the
Middle East. Most of these patients had a history of travel to the Ara-
bian Peninsula, or they were in contact with infected people, of which
some were camel shepherds. After the Middle East, the second out-
break of MERS occurred in 2014-2017 in South Korea, indicating the
circulation of the virus and a more significant concern for the world
health community. At that time, MERS was responsible for infecting
2458 people and 848 deaths (about 35% mortality).4
In December 2019, a cluster of Covid-19 patients with symptoms
of pneumonia complicated with acute respiratory distress syndrome
(ARDS) was observed in Wuhan, China.5,6 In comparison to SARS and
MERS, Covid-19 has a higher rate of spread and became a pandemic in
about 4 months. The high power of this large-scale dissemination led to
the quarantine of several cities in different countries.7 Based on the
World Health Organization (WHO) 57th report on 17 March 2020;
worldwide there have been 179 112 confirmed cases, with 7426 deaths
(about 4% mortality).8 There is no vaccine or targeted treatment cur-
rently available for COVID-19 infection. Treatment is mostly supportive,
although multiple experimental antiviral medications are being evalu-
ated.9,10 Thus, prevention and rapid diagnosis of infected patients are
crucial. The trigger for rapid screening and treatment of COVID-19
patients is based on clinical symptoms, laboratory, and radiographic
findings that are similar to SARS and MERS infections.
In this study, we attempted to distinguish the clinical symptoms,
laboratory findings, radiographic signs, and outcomes of confirmed
COVID-19, SARS, and MERS patients. All findings are compared to
determine unique features among each of them. These data could be
helpful in the early diagnosis and prevention of infection as well as
providing more reliable epidemiological data on a large-scale for
health care policies and future studies.
2 | METHODS
2.1 | Search strategy
This study was conducted according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Statement
(PRISMA) guidelines, and it has been registered in the PROSPERO
database (ID 176106).11 We searched all studies published up to
28 February 2020, from the following databases: Embase, Scopus,
PubMed, Web of Science, and the Cochrane library. Search medi-
cal subject headings (MeSH) terms used were: “COVID-19,”
“Coronavirus,” “Severe Acute Respiratory Syndrome,” “SARS
Virus,” “severe acute respiratory syndrome coronavirus 2”, “Coro-
navirus Infections,” “Middle East Respiratory Syndrome
Coronavirus,” and all their synonyms like “Wuhan Coronavirus,”
“SARS-CoV-2,” and “COVID-19,” “2019-nCoV” and MERS. More-
over, we searched for unpublished and grey literature with Google
scholar, Centre for Disease Controls (CDC) and WHO databases.
We also examined references of included articles to find additional
relevant studies. There was no language restriction, and all
included studies were written in English or Chinese languages; the
latter was translated by https://translate.google.com/. Additional
search strategy details are provided in Table S1.
2.2 | Study selection
Duplicate studies were removed using EndNote X7 (Thomson
Reuters, New York, NY, USA). Records were initially screened by title
and abstract by independently four authors (AP, SG, AK, and RF). The
full-text of potentially eligible records was retrieved and examined,
and any discrepancies were resolved by consensus.
2.3 | Eligibility and inclusion criteria
Studies had to fulfill the following predetermined criteria to be eligible
for inclusion in our meta-analysis. All case-control, cross-sectional,
cohort studies, case reports, and case series peer-reviewed studies
were included if they reported the number of confirmed cases of
patients with demographic data, [AND] [OR] clinical data, [AND]
[OR] laboratory data, [AND] [OR] risk factor data.
2.4 | Exclusion criteria
Studies were excluded if they did not report the number of confirmed
cases. Letters to the editor, individual case reports, review articles,
and news reports were also excluded. Duplicate information from the
same patient was combined and counted as a single case when the
data was reported twice.
2.5 | Data extraction
All COVID-19 included publications were published in 2020, and
all patients were from China. The following items were extracted
from each article: first author, center and study location in China,
countries, sample collection time, patient follow-up time, the
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reference standard for infection confirmation, number of con-
firmed cases, study type, and all demographic, clinical, laboratory
data, and risk factor data. Three of our authors (SG, AK, and RF)
independently extracted data, and all extracted data were checked
randomly by another author (AP); differences were resolved by
consensus.
2.6 | Quality assessment
Quality assessments of studies were performed by two reviewers
independently according to the Critical Appraisal Checklist rec-
ommended by the Joanna Briggs Institute,12 and disagreements were
resolved by consensus. The checklist is composed of nine questions
that reviewers addressed for each study. The “Yes” answer to each
question received one point. Thus, the final scores for each study
could range from zero to nine (Table S2).
2.7 | Analysis
Data cleaning and preparation were done in Microsoft Excel 2010
(Microsoft©, Redmond, WA, USA), and further analyses were carried
out via Comprehensive Meta-Analysis Software Version 2.0 (Biostat,
Englewood, NJ). Determination of heterogeneity among the studies
was undertaken using the chi-squared test (Cochran's Q) to assess the
appropriateness of pooling data. Depending on the heterogeneity test,
we used either random or fixed-effect models for pooled results. In
the case of high heterogeneity (I2 > 50%), a random effect model
(M-H heterogeneity) was applied, while in low heterogeneity cases
(I2 < 50%), a fixed-effect model was used.13 Percentages and means ±
SDs were calculated to describe the distributions of categorical and
continuous variables, respectively. P values reflect study heterogene-
ity with <.05 being significant. We also used the funnel plot, Begg's,
and Egger's tests based on the symmetry assumption to detect publi-
cation bias (Figure S1).
F IGURE 1 Flow diagram of literature search and study selection (PRISMA flow chart)
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3 | RESULTS
3.1 | Characteristics of included studies
The process of study selection is displayed in Figure 1. A total of
36 115 reports were screened for the analysis of patients with
COVID-19, 36 014 were excluded after the title, and abstract screen-
ing and the full text of 81 reports were reviewed in full text. We
excluded studies that did not report sufficient data. Out of
114 included studies, 20 studies met the inclusion criteria for COVID-
19, 51 for SARS, 43 for MERS. The characteristics of the selected arti-
cles are summarized in Table 1. Of the 20 COVID-19 studies that
were included in the analysis, 19 studies were in English, and one was
in Chinese.21 All COVID-19 studies were retrospective, published in
2020, and all patients were from China.
3.2 | Quality assessment
Quality assessment of included studies was performed based on
the Critical Appraisal Checklist, and the final quality scores of the
included studies are represented in Table S2. In brief, studies by
Chen et al,14 Wang et al,17 Huang et al,18 Guan et al,19 Zhang
et al,24 Cheng et al,25 Li et al,28 Xu et al,30 and Song et al31 had the
highest quality of the COVID-19 studies available in the purpose
of this study.
3.3 | Demographics, baseline characteristics, and
clinical characterization
Overall, 52 251 confirmed patients with COVID-19 infection, 10 037
with SARS, and 8139 with MERS were included in the meta-analysis,
of which 53.7% (95% CI 50-56.8, P < .001) of COVID-19, 43% (95%
CI 40-46.5, P < .001) of SARS, 66% (95% CI 63-69, P < .001), of MERS
included patients were male. Funnel plots for included studies did not
detect significant publication bias (Figure S1). Table 2 shows that most
COVID-19 85.6% (95% CI 73-93, P < .001), SARS 96% (95% CI
93-97.6, P < .001), and MERS 74% (95% CI 63.5-83.5, P < .001) had a
fever (Figure S2). Cough was the second most common symptom pre-
senting in COVID-19 63% (95% CI 55.5-70, P < .001), SARS 54.2%
(95% CI 49-59, P < .001), and MERS 61% (95% CI 51-70, P < .001) of
patients (Figure S3).
Shortness of breath was less common in Covid-19 patients 17%
(95% CI 9-31.5, P < .001), in comparison to SARS 32% (95% CI 20-46,
P < .001), and MERS 51% (95% CI 41-63, P < .001). Likewise, chills
were less common in Covid-19 patients 17% (95% CI 6.5-38,
P < .001), in comparison to SARS 57.5% (95% CI 50-64, P < .001), and
MERS 41% (95% CI 16-72, P < .001).
A much smaller proportion of COVID-19 patients had sore
throat 12.3% (95% CI 7.8-17, P < .06), headache 12.2% (95% CI
8.3-18, P < .001), diarrhea 7.3% (95% CI 4.6-11.4, P < .001),






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PORMOHAMMAD ET AL. 11 of 18
(95% CI 2.7-13, P < .001), or runny nose 6% (95% CI 1-14,
P < .001). More detail information about demographics and clinical
characterization of COVID-19 (Table S3), SARS (Table S4), and
MERS patients (Table S5) demonstrated in the supplementary
material.
3.4 | Risk factors and clinical characteristics of
patients infected with COVID-19
The greatest risk for COVID-19 patients 69.5% (95% CI 54.5-81,
P < .001) up to 28 February 2020, is a history of recent travel to Wuhan,
contact with people from Wuhan, or were Wuhan residents, and 24.3%
(95% CI 9.6-49, P < .001) had exposure at the seafood market(s). The
most common comorbid chronic condition for COVID-19 and SARS is
hypertension, and for MERS diabetes, 46% (95% CI 34.5-58, P < .001).
Overall, 41.2% (95% CI 20-66, P < .001) of COVID-19 patients had a
history of chronic diseases. Acute respiratory syndrome (ARDS)
occurred more frequently in SARS 51% (95% CI 6-94, P < .001) com-
pared to MERS 29% (95% CI 14-51, P < .001) and COVID-19 10.6%
(95% CI 4-26.7, P < .001). More detailed information about comorbid
conditions of COVID-19 (Table S6), SARS (Table S7), and MERS
(Table S8) patients is demonstrated in the supplementary material.
3.5 | Chest X-ray and CT scan findings in patients
infected with COVID-19
Analysis showed that 84% (95% CI 78-8.5, P < .001) of COVID-19
patients, 86% (95% 77-92, P < .001) of SARS patients, and 74.7% (95%
56.5-87, P < .001) of MERS patients had abnormal radiological findings
on chest X-ray and CT scans. The radiological abnormalities in COVID-19
patients were bilateral involvement of chest X-ray 76.8% (95% CI
62.5-87, P < .001), consolidation 75.5% (95% CI 50.5-91, P < .001), and
ground-glass opacity 71% (95% CI 40-90, P < .001) (Table 2). More
detailed information about chest X-ray and CT scan findings of COVID-
19 (Table S9), SARS (Table S10), and MERS patients (Table S11) is demon-
strated in the supplementary material.
3.6 | Outcome
Most COVID-19 confirmed patients required hospitalization 85.4% (95%
CI 68-94, P < .001) and 20.6% (95% CI 6.7-48, P < .001) were deemed to
be in critical condition. The mortality rate of COVID-19 confirmed cases
was 5.6% (95% CI 2.5-12.5, P < .001), SARS 13% (95% 9-17, P < .001),
and MERS 35% (95% CI 31-39, P < .001) (Figure 2).
3.7 | Laboratory findings of patients infected with
COVID-19
The laboratory findings showed that among a subset of patients 4.5%
(2361/52 251) where data were available, thrombocytosis in COVID-
19 patients was 61% (95% CI 45-72, P < .001) which is more than
double that of SARS at 41.5% (95% CI 35-56.4, P < .001) and MERS
30% (95% CI 22-58, P < .001) (Table 3). The most SARS patients 71%
(95% CI 62-78, P < .001) had decreased lymphocytes, and the most of
MERS patients had decrease platelets 62% (95% 52-74, P < .001) in
their laboratory findings (Table 3).
F IGURE 2 Forest plot of the meta-analysis on mortality outcome in patients with confirmed COVID-19 (upper left), SARS (upper right), and
MERS (lower left)
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4 | DISCUSSION
Prior to 2002, coronaviruses were associated with mild respiratory ill-
ness, but with the emergence of SARS in 2002, MERS in 2012, and
now in late 2019, COVID-19, it is established that coronaviruses
infections can be associated with severe respiratory disease. The virus
is transmitted via respiratory droplets or infected inanimate objects,
and with its rapid spread worldwide in just a few months, the WHO
has officially declared the COVID 19 outbreak a pandemic.22,126
Our results show that fever and cough were the most common
clinical symptoms in COVID-19, SARS, and MERS. Among 52 251
patients with COVID-19 infection, while fatigue, sputum production,
and myalgia (muscle soreness) were the next most frequent clinical
symptoms; diarrhea, rhinorrhea, nausea, and vomiting were less com-
mon. Within the 10 037 confirmed SARS patients, the next most fre-
quent clinical manifestations were chills, myalgia, headache, and
dyspnea. Moreover, 8139 MERS patients commonly exhibited short-
ness of breath, chills, and dyspnea.
























2361 11 5.1 (×109
per L)
(3.3-7)




Increased 13.3 (%) 28 (%) 30 (%)
Decreased 26 (%) 32 (%) 41 (%)








Increased - 5 (%) -
Decreased - 17.5 (%) -
Lymphocytes 1.1-3.2 0.98 (×109
per L)
(0.9-1.06)
2361 11 0.74 (×109
per L)
(0.66-0.816)
825 10 - 210 4
Decreased 62.5 (%) 71 (%) 50 (%)
Platelets 125-350 186.5 (×109
per L)
(167-205)
2200 9 179 (×109
per L)
(159-199)
1912 5 - 178 3
Decreased 13 (%) 0.2 (%) 62 (%)
Increased 61 (%) 41.5 (%) 30 (%)
CRPa 0-0.5 29.6 (mg/L)
(16.7-42.5)
290 5 22.8 (mg/L)
(22-35)
256 2 - 156 3
Increased 81 (%) 93 (%) 45 (%)
Hemoglobin 130-175 119 (g/L)
(106-132)
2062 8 - - - - - -
ESRb 0-15 42 (mm/h)
(46-57)












99 2 - - - - - -
LDHc 120-250 280
(268-294)
1783 9 - - - - - -
Increased 70.3 (%)
Abbreviations: CRP, C reaction protein; ESR, erythrocyte sedimentation rate; WBCs, white blood cells.
aIncreased or decreased refers to values above or below the normal range.
berythrocyte sedimentation rate.
cLactate dehydrogenase.
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Shortness of breath was less common in COVID-19 patients
(17%), in comparison to SARS (32%) and MERS (51%). Likewise, chills
were less common in COVID-19 patients (17%), in comparison to
SARS (57.5%) and MERS (41%). Therefore, these clinical symptoms
should help distinguish the various coronavirus infections from each
other.
Our analysis indicated recent travel to Wuhan, contact with people
from Wuhan or residency in Wuhan, exposure to persons with respira-
tory symptoms, and seafood market exposures were common risks
among those contracting COVID-19. Furthermore, chronic respiratory
disease and recent travel to SARS endemic areas were most common
among those contracting SARS. In addition, 28% of SARS patients and
21% of MERS confirmed patients were health care workers, which is
higher than COVID-19 cases (3%). This data indicate that in coronavirus
outbreaks, isolating infected individuals is one of the most important
ways of controlling transmission.
We find that most of the patients with COVID-19, SARS, and
MERS had abnormal chest radiological findings. With ground-glass
opacity and consolidation in COVID-19 patients being more frequent
than in SARS and MERS patients. Other studies reported that signifi-
cant similarity exists when comparing radiological findings of COVID-
19 patients with those suffering from complicated viral pneumonia
such as SARS and MERS.22,32 Therefore, there appear to be no dis-
tinguishing radiological findings when comparing human
coronaviruses.
The mortality rate was 5.6%, 13%, and 35% among COVID-19-,
SARS-, and MERS-infected patients, respectively. While the mortality
rate among COVID-19 patients is lower than SARS and MERS,
COVID-19 is proving to have a higher contagious potency, resulting in
a higher number of deaths. It should be recognized that these num-
bers are biased due to the data set, including publications related to
screening practices (eg, only those with symptoms being screened)
increased the percentage value. The actual mortality rate from
COVID-19 is almost certainly much lower than that found in this
study. As more data emerges from screening asymptomatic or mildly
symptomatic individuals in China and around the world, the exact
mortality rate will be better understood.
Among COVID-19, SARS, and MERS patients, leukocytosis was
found in 13.3%, 28%, and 30%, respectively, and leukopenia in 26%,
32%, and 41%, respectively.
Most of the patients with coronavirus had abnormal chest radio-
logical findings. On the other hand, runny nose and rhinorrhea are less
common symptoms in coronavirus-infected patients,127 which indi-
cates the virus preferentially affects the lower respiratory tract. A
study by Zhao et al showed that ACE2 is a COVID-19 virus receptor
and that it is typically expressed on pulmonary alveolar epithelial
cells.128 Another study reported that following COVID-19 infection
deregulated cytokine/chemokine response and higher virus titer cau-
ses an inflammatory cytokine storm with lung immunopathological
injury.129 Inflammation related to the cytokine storm in the lungs may
then spread throughout the body via the circulation system.
COVID-19 patients have been reported to have increased plasma
concentration of inflammation-related cytokines, including interleukin
(IL)-2,6,7,10, tumor necrosis factor-α (TNF-α), and monocyte chemo-
attractant protein I (MCP-I) especially in moribund patients.130 Our
data collected here show that ARDS occurred in 10.6% of reported
patients with COVID-19 infection. A previous study showed that
ACE2 (main receptor of COVID-19) expression is higher in people
with pulmonary ARDS and acute respiratory injury.131
Several limitations of this study exist. Publication bias and study
heterogeneity are unavoidable in this type of study. Therefore, it should
be considered when interpreting the outcomes of the reports and our
final data set. Furthermore, this study likely overestimates disease
severity due to a lack of screening for asymptomatic or mildly symptom-
atic individuals and subsequent publication bias related to these factors.
Likely, many infected persons have not been detected, thus falsely ele-
vating the rates of hospitalization, critical condition, and mortality. The
lower quality analysis and reporting in some of the included publications
is another limitation of the study. To prevent language bias, we included
reports in languages other than English. Additionally, we searched for a
variety of sites and databases to prevent internet platform bias. Using
Egger's regression test, we did not find significant publication bias. Jour-
nal bias is an issue facing those who carry out a meta-analysis, yet it
does not usually affect the general conclusions.132 However, we cannot
reject the occurrence of other biases in this study, such as choice bias,
since several journals are not indexed in Embase, Scopus, PubMed,
Web of Science, and the Cochrane library and unpublished data from
some regions of the world.
5 | CONCLUSIONS
Fever and cough are the most common symptoms of COVID-19-,
SARS-, and MERS-infected patients. The mortality rate in COVID-19
confirmed cases was lower than SARS- and MERS-infected patients.
Clinical outcomes and findings may be biased by reporting only con-
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